The first FDA-approved antibody-drug conjugate therapy for metastatic UC (mUC), enfortumab vedotin (EV), targets NECTIN4, a protein that is expressed on the cell surface of bladder cancer cells, and is now the frontline, standard of care treatment for patients with advanced urothelial carcinoma in the U.S.